Information on the Target

Jinko is an innovative start-up focused on enhancing the quality of life for individuals affected by cancer. The company provides personalized supportive care designed to improve patients' experiences throughout their treatment journeys and after. Jinko adopts a holistic, multidisciplinary approach, offering services such as dietary counseling, psychological support, adapted physical activities, socio-aesthetics, and osteopathy. These services are delivered by a network of certified and compassionate practitioners dedicated to supporting patients' diverse needs.

Research shows that more than 80% of cancer patients experience either physical or psychological effects due to their condition or its treatment. Various scientific studies underscore the effectiveness of supportive care in significantly reducing mortality rates by 37% and recurrence rates by 24%, while also alleviating side effects and enhancing treatment efficacy. The importance of supportive care is affirmed by public sentiment, with three out of four French citizens acknowledging its significance comparable to traditional treatment methods.

Industry Overview in France

The cancer care industry in France is characterized by a growing recognition of the essential role of supportive care in enhancing patient outcomes. As the population ages and the incidence of cancer rises, there is an increasing demand for services that address the comprehensive needs of patients. Supportive care solutions are gaining traction among healthcare professionals, as they understand that traditional medical interventions must be complemented with holistic care to achieve the best results.

In France, the integration of digital technologies in healthcare has opened new avenues for delivering personalized supportive care. Mobile applications and telehealth platforms enable patients to receive consultations and guidance without geographical constraints, improving access to necessary services. This transformation is critical in ensuring that all patients can benefit from tailored supportive care pathways, irrespective of their location.

The industry faces challenges, particularly in terms of accessibility and affordability. While the demand for supportive services is evident, many patients encounter financial barriers that hinder their ability to access these essential resources. Jinko's mission to make its services more affordable is a timely response to this pressing issue, aiming to democratize access to quality care for everyone affected by cancer.

Moreover, the collaboration between technological startups and healthcare systems is vital for cultivating innovative approaches to patient care. As new players enter the market, they challenge the status quo, introducing fresh ideas and solutions that enhance patient quality of life while navigating the complexities of the healthcare landscape.

The Rationale Behind the Deal

The recent 2-million-euro funding round will significantly propel Jinko's mission to expand its personalized supportive care services. By securing investment from prominent players like 360 Capital and AFI Ventures, Jinko aims to increase its partnerships, enhance visibility among patients and healthcare professionals, and further develop its digital platform. This funding is integral to realizing Jinko’s goal of supporting 1,000 patients in the following year while innovating to provide effective care.

Additionally, the funding will support the long-term ambition of making supportive care more accessible and, ultimately, free for all cancer patients. This commitment resonates with Jinko's vision of removing financial barriers to ensure that every individual affected by cancer can benefit from essential supportive services.

Information About the Investor

360 Capital is a leading venture capital firm focused on supporting innovative startups in various sectors. The firm combines financial investment with strategic expertise to nurture promising companies. Clara Cornu and Alexandre Mordacq, representatives from 360 Capital, expressed their enthusiasm for Jinko's approach, recognizing the pressing need for enhanced supportive care solutions in the industry.

AFI Ventures is a specialized fund that champions impact-driven startups addressing social and environmental challenges. Managed by Ventech, with a capital of 31 million euros, AFI Ventures seeks to support entrepreneurs who develop equitable and sustainable solutions for diverse sectors within France and Europe. Their involvement in Jinko underscores their belief in the start-up's potential to impact the underserved area of supportive care for cancer patients.

View of Dealert

The investment in Jinko appears to be a strong and strategic move within the healthcare realm, particularly in the context of supportive care for cancer patients. With a proven model that aims to address the growing demand for personalized care, Jinko offers a unique solution that integrates technology with compassionate human support. The startup's initiative to make supportive care accessible and affordable positions it favorably in the market.

Furthermore, the growing body of research supporting the efficacy of supportive care strengthens the rationale for this investment. As patients increasingly prioritize holistic treatment approaches, Jinko is well-positioned to capture a significant share of this emerging market. The 38% increase in quality of life reported during the pilot phase demonstrates the potential for effective outcomes, bolstering investor confidence.

Partnerships with established investors like 360 Capital and AFI Ventures not only provide the necessary financial backing but also lend expertise in navigating the complexities of the healthcare landscape. The support from such experienced firms enhances Jinko's credibility with healthcare providers and further promotes adoption of its services.

Overall, Jinko's innovative approach shows promise not just in terms of financial returns but also in its capacity to make a meaningful difference in patients' lives. As the startup gains traction and expands its reach, it has the potential to redefine how supportive care is delivered, ultimately transforming the patient experience in cancer care.

View Original Article